New Drug Development

Our Resources

The Pediatric Early Phase-Clinical Trial Network (PEP-CTN) successfully leverages the database infrastructure and resources of the parent Children’s Oncology Group (COG) while maintaining its own administrative and operational infrastructure to ensure rapid development, implementation and reporting of specialized and complex early phase clinical trials.

The PEP-CTN has expert resources for the conduct of translational biology, pharmacokinetic, and pharmacogenetics studies, as well as infrastructure to facilitate image transfer of specialized correlative imaging studies for central review and analyses.

Industry Partners

Our experienced investigators have in-depth experience in the design and conduct of early phase cancer trials in children, with the ability to efficiently and inclusively accrue participants, as well as deliver data to support regulatory submissions in a time and cost-effective manner.

The organization and structure of the PEP-CTN will ensure the efficient development and implementation of state-of-the-art early phase trials incorporating broad multidisciplinary input from within the PEP-CTN, from NCI, as well as from pharmaceutical/biotechnology industry partners. The COG and PEP-CTN have established productive working partnerships with a broad range of industry partners. The goal is to ensure that the most promising new agents for children with cancer are studied in a timely manner utilizing state-of-the-art pediatric drug development approaches.